Introduction
Antiarrhythmic strategies have changed dramatically during the last decade. The Cardiac Arrhythmia Suppres-Ž . sion Trial CAST reported the harmful effects of flecainide, encainide and moricizine in patients with ventricular premature beats who had had myocardial infarction w x 162,163 . Compared with placebo, these three drugs were associated with increased mortality from cardiac death. Numerous meta-analytic studies also provided evidence that drugs that act fundamentally by blocking cardiac Ž sodium channels Class I agents in Vaughan Williams' w x. classification 171 may, in general, have the potential to increase mortality in patients with significant structural heart disease even though they may suppress cardiac arw x rhythmias 2,31,49,99, 161, 187 . The use of Class I drugs in subsets of patients at risk for sudden death is therefore declining. Along with this trend, the therapeutic role of drugs that have antiarrhythmic actions mainly through a Ž . prolongation of action potential duration APD and refrac-Ž . toriness Class III agents have attracted renewed interest w x 29,56,86,135,148-151 . Class III agents include relatively old compounds having complex electropharmacological Ž profiles e.g., bretylium, sotalol and especially amio-. darone and newer compounds that exhibit the sole propen-Ž sity to lengthen APD and the refractory period i.e., sematilide, dofetilide, d-sotalol, ibutilide, ambasilide, . risotilide, almokalant, MK-499, E-4031 and MS-551 w x 86, 147-149 . It was shown in large-scale clinical studies that sotalol is superior to Class I agents in preventing and terminating Ž life-threatening ventricular tachyarrhythmias ventricular
. w x tachycardia and fibrillation, VTrVF 93,94 . The advan-) Ž .
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tage of sotalol might have been mainly due to the drug's action to prolong APD through the entire heart. This hypothesis has led to research to develop a new series of pure compounds devoid of other associated properties. d-Sotalol is one of these new and pure Class III agents, in which the beta-blocking action of the racemic form of sotalol is minimized in order to eliminate its possible undesirable effects on hemodynamics. The long-term clinical effect of d-sotalol has been tested in a large-scale Ž double-blind, placebo-controlled study Survival with Oral . d-Sotalol; SWORD in post-infarct patients at risk for high w x mortality 174 . The trial was initially planned to enrol 6400 patients, but was stopped prematurely when 3119 patients had been enrolled because of the significantly higher total mortality in the drug-treated patients than in the placebo group. The adverse effect of d-sotalol on mortality could be due to proarrhythmic reaction, and most other pure Class III compounds might have a similar deleterious effect. These possibilities remain to be tested or confirmed. The outcome of SWORD, however, had a great impact on the development of new antiarrhythmic drugs. A large number of pure Class III compounds under investigation have been discontinued from clinical development w x 151 . Emphasis is therefore shifting to the compounds w x with a multifaced pharmacological profile 83, 128, 151 Žwith multiple molecular targets in the framework of the w x. Sicilian Gambit 96,160 or to drugs with more specific targets based on advances in the understanding of ion channels and their molecular physiology and pharmacology.
Many investigators now believe that amiodarone is the most promising drug in the treatment of life-threatening Time for primary review 17 days.
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Ž . PII S 0 0 0 8 -6 3 6 3 9 7 0 0 1 1 4 -4 ( )supraventricular and ventricular tachyarrhythmias w x 4,83,103,128,151 . Amiodarone was synthesized in Bel-Ž . gium Labaz Inc. originally as an antianginal agent in 1962 during a systematic search for potent coronary vaw x sodilators 143 . The antiarrhythmic effects of amiodarone w x in experimental animals appeared in 1969 27 . A great deal of experimental and clinical studies carried out during the subsequent period in the 1970s and 1980s confirmed the extremely potent antiarrhythmic activity of amiodarone, and it has been used to treat patients with a wide variety of tachyarrhythmias, mainly in European countries w x and in South America 42,52,92,109,143,145,146 . In the United States, clinical use of amiodarone had long been more limited because of its significant extracardiac toxicity involving the liver, lungs, and thyroid. The use of amiodarone was approved in 1985 by the Food and Drug Administration as a 'last resort' drug only for life-threatenw x ing ventricular arrhythmias refractory to other agents 92 . It was also approved in Japan in 1992 with a similar w x indication 68 . The advantage of amiodarone over other antiarrhythmic drugs has been demonstrated in many clinical trials in the 1990s in the treatment of atrial fibrillation and flutter, the treatment of non-sustained ventricular tachycardia in patients with cardiomyopathy and congestive heart failure, the treatment of patients who have recently had a myocardial infarction, and the prevention of recurrent sustained ventricular tachycardia and ventricular w x fibrillation 4,128,151 . Unlike other antiarrhythmic agents, amiodarone has not been shown to increase mortality in w x any population studied 128 .
Amiodarone has long been referred to as a prototype of Class III antiarrhythmic agents because it was demonstrated in early experimental studies in 1970s that this compound prolongs both APD and the refractory period of cardiac muscle when administered chronically w x 52,143,188 . Many studies during the past two decades have shown that the pharmacological action of amiodarone is very complex. For instance, it possesses an inhibitory effect on the fast sodium channel as well as on the slow w x calcium channel 92,109 . Amiodarone also has non-competitive antisympathetic effects, and modulates thyroid w x function and phospholipid metabolism 71,145,147 . Which action or combination of actions is fundamental and salutary for its potent antiarrhythmic activity is not known.
One reason the pharmacological profile of amiodarone remains so mysterious is the difference in its acute and w x chronic effects 63,73,145,146 . Clinical electrophysiological studies on amiodarone have revealed that its main acute effect is suppression of conductivity of the atrioven-Ž . tricular AV node with minimal effect on the effective refractory periods of the atrial muscle, ventricular muscle, and the bypass tract or the His-Purkinje tissue when the w x drug is administered intravenously 51,58,98,177 . There is Ž . no significant effect on the corrected QT intervals QTc in ECGs. QRS duration is prolonged only at fast stimulus w x frequencies 98 . In contrast, when administered orally for more than several weeks, amiodarone predictably length-Ž . ens repolarization QTc and refractoriness in most cardiac tissues with little or no change in QRS duration and a Ž . modest increase in atrio-His bundle AH or His bundle-Ž . w x ventricular HV intervals 38,102,145,177 . There is now substantial evidence that such a difference, also noted in animals, is not explicable in terms of the pharmacokinetics Žserum and myocardial tissue concentrations of amio-
. w x darone and its active metabolite 145,146 .
In the present article, we review the current knowledge on the electrophysiological effects of amiodarone on the heart based on acute and chronic experimental studies in single channel, single cell, multicellular tissue preparation and whole heart levels, and discuss the molecular and cellular modes of action of this unique antiarrhythmic agent.
Acute effects of amiodarone
Ž Amiodarone is a highly lipophilic drug lop P s 5.95 w x. and p K a s 8.7 at 378C 28 and is almost insoluble in water or aqueous buffer solution. In experiments to assess the acute effects of amiodarone, this compound is usually dissolved in crystalloid solutions using several different Ž . types of vehicles Table 1 . In previous reports, amiodarone was often dissolved first in 50-100% ethanol, and then added to physiological salt solutions containing plasma Ž .w x or serum albumin 0.1-1% 57,58,63,73,120,127,182,183 . Vehicles specifically prepared for intravenous injection in Ž . clinical use Polysorbate 80 or Tween 80 were also w x employed 6,7,11,39,89,113,119,130 . At higher drug concentrations, however, amiodarone does not completely dissolve, and suspension or precipitation occurs. In some studies in which amiodarone was dissolved directly in w x crystalloid solutions 46,62,111,112 , this might have posed a more serious problem, and the concentrations presented in those articles must have been much higher than those at the site of drug action. The vehicles, above a certain concentration, are known to cause their intrinsic effects on w x the electrophysiological properties of cardiac tissues 164 . Amiodarone penetrates deeply into the lipid matrix of the membrane, and is released from cardiac tissues very slowly when washed out. Consequently, acute effects of amiow x darone cannot be reversed during the experiments 131 . These limitations often make it difficult to interpret and compare data obtained in experiments using acute perfusion or superfusion with this drug.
Action potentials
In cardiac cells or tissues whose excitation depends on activation of fast sodium channels, the most consistent change of action potential configuration elicited by acute application of amiodarone is a decrease of the maximum Ž . In ventricular muscle, a moderate prolongation of APD Ž . Ž . 10-23% with amiodarone 5-58 mM was reported in Ž several studies using guinea pigs, ferrets and dogs Table  . 1 . In our experiments in rabbit papillary muscle, however, 10 mM amiodarone caused a significant 12-26% shorten-Ž . w x ing of APD at y70 mV level 73 . We also observed a significant shortening of APD in single rabbit ventricular w x w x cells 63 . Kadoya et al. 62 observed no significant changes in APD and ERP in ventricular muscle from rabbits. In Purkinje fibers, most of the previous studies Ž using dogs showed a significant shortening of APD and . Ž . ERP with acute amiodarone For the acute effects of amiodarone on cardiac tissues whose excitation depends on activation of slow calcium channels, only limited information is available. In sinoa-Ž . trial SA node preparations of isolated rabbit atria, amio-Ž . darone 15-50 mM was shown to cause significant decreases in the action potential amplitude, the slope of Ž . phase 4 depolarization pacemaker potential and the rate w x w x of spontaneous excitation 46,62,183 . Nattel et al. 107 demonstrated frequency-dependent inhibition of slow action potentials elicited in dog Purkinje fibers exposed to Ž . high extracellular potassium 25 mM and isoproterenol. In their study, 5 mM amiodarone caused a significant decrease in V when the preparations were stimulated at max 1.4-2.0 Hz; the higher the stimulation-frequency, the greater the V inhibition. In the presence of 5 mM max amiodarone, V recovery of the slow action potential max Ž showed a much slower recovery with a time constant of . Ž 940 ms than that before the drug application time con-
. w x stant of 74 ms 107 . Slow action potentials in isolated guinea pig ventricular muscles exposed to high extracellu-Ž . lar potassium 15-24 mM and isoproterenol were inhibw x ited by acute amiodarone as well 7,89 . Acute application Ž . of amiodarone 50-88 mM was also found to suppress the depolarization-induced spontaneous action potentials Ž . w x abnormal automaticity in ventricular muscles 91 and in w x Purkinje fibers 157 .
Based on these experimental studies in vitro, it seems reasonable to describe the major and consistent acute effects of amiodarone as an inhibition of depolarization of action potentials which depends on activation of either fast sodium channels or slow calcium channels, and the inhibition is enhanced in a use-and frequency-dependent manner. On the other hand, acute amiodarone has no consistent effects on the repolarization phase of action potentials. Such characteristics correlated well with the acute effects of amiodarone on conductivity and refractoriness in whole hearts perfused in vitro or in vivo. In isolated hearts from rabbits and guinea pigs, acute perfusion with amiodarone Ž . 1-10 mM resulted in a depression of AV nodal conduction but failed to prolong ventricular repolarization and w x refractoriness 122,131,153,154 .
Ž Intravenous application of amiodarone 1.25-25 . mgrkg to anesthetized dogs resulted in a decrease in sinus rate, a prolongation of effective and functional refractory periods of the AV node, and a frequency-dependent conduction delay in the AV node and in the ventricle Ž greater inhibition of AV nodal conduction than intraven-. tricular conduction . The QT interval was unaffected by acute amiodarone, and a prolongation of ERP in ventricuw x lar muscle was minimal or negligible 30,60,107,158 . 
Ionic currents
Acute effects of amiodarone on cardiac ionic currents w x were first examined by Neliat et 
Na
The tonic block was enhanced at less negative holding potential, consistent with a shift in the steady-state avail-Ž . ability curve to more negative potential y16 mV . The use-dependent block was enhanced in conjunction with Ž . Ž . increase in rate 0.5-5.0 Hz and duration 2-200 ms of depolarizing pulses. The recovery of i from inactivation Na was significantly delayed in the presence of amiodarone. They therefore concluded that amiodarone may block both rested and inactivated sodium channels with higher affinity Ž to the inactivated ones i.e., with a minimal affinity to the . activated channels . This is essentially in accord with the w x findings in experiments using V measurement 57,91 . From the findings described above, the acute effects of amiodarone on cardiac ionic currents can be summarized as follows. Amiodarone inhibits both inward and outward currents. The inhibition of inward Na q and Ca 2q currents is enhanced in a use-and voltage-dependent manner. Suppression of excitability and conductivity by amiodarone would, therefore, be greater in cardiac tissues stimulated at higher frequency, and in those with less negative resting 
Chronic effects of amiodarone
During the long-term treatment of animals or humans with amiodarone, not only the parent drug, but also its Ž . active metabolite, desethylamiodarone DEA , accumulates extensively in both the plasma and the myocardium w x 106,145,146 . In this section, we first describe the chronic effects of amiodarone on action potentials and ionic currents, and then discuss the contribution of DEA to those effects of amiodarone.
Action potentials
Investigators of data generally agree that the major effect of chronic amiodarone is a prolongation of APD of cardiac tissues. This was first demonstrated by Singh and w x Vaughan Williams 142 in atrial and ventricular muscles from rabbits: after treatment of the rabbits with intraperi-Ž . toneal application of amiodarone 20 mgrkgrday for 6 weeks, APD of atrial and ventricular muscles was in-90 creased by 34 and 30%, respectively, whereas the resting membrane potential and amplitude of action potential were unaffected. Subsequent studies have shown that treatment of rabbits with amiodarone for several weeks results in moderate APD prolongation not only in atrial and ventricular muscles but also in SA nodes and AV nodes w x 58,62,70,172 . A similar APD prolongation by chronic amiodarone was also reported in ventricular muscles from w x w x w x guinea pigs 6,91,169 , rats 78 , and dogs 81,130,181 as w x well as in Purkinje fibers from dogs 41 . Such APD prolongation was associated with a comparable prolongation of ERP.
There is considerable controversy regarding the Class I w x action of chronic amiodarone. Mason et al. 91 showed a marked use-dependent V inhibition in guinea pig papilmax lary muscle after chronic treatment with amiodarone, which was comparable to the acute effects of the drug. In support of this finding, a rate-dependent decrease in conduction velocity in association with a decrease in V was demon- We studied the chronic effects of amiodarone in a series w x of experiments using rabbits 59,63,73 . The animals were treated for 4 weeks with oral amiodarone at doses ranging from 20 to 100 mgrkg daily. On the last day of drug treatment, peripheral blood was sampled to measure serum amiodarone and the ECGs of extremity leads were recorded. The rabbits were then sacrificed to obtain the whole hearts for Langendorff perfusion, right ventricular papillary muscles for superfusion, or single ventricular cells through enzyme digestion. Untreated rabbits of corresponding weight were used as controls. ECGs were not affected at a daily dose of 20 mgrkg amiodarone. In rabbits that received 50 or 100 mgrkg amiodarone per day, the RR, QT and QTc intervals were significantly prolonged in comparison with controls. PQ and QRS rew x mained unchanged 59,73 . Serum and myocardial tissue amiodarone concentrations in rabbits that received 50 or 100 mgrkg of amiodarone per day were 0.14-0.18 mgrml w x and 1.47-3.63 mgrg wet weight, respectively 59,73 .
Papillary muscles isolated from amiodarone-treated rabbits showed longer APD than controls. Under constant stimulation at 1.0 Hz, APD at y70 mV repolarization in the muscles treated with 50 or 100 mgrkg amiodarone was prolonged significantly by 13 In control rabbit papillary muscles, APD was the longest at a stimulation frequency of 0.5 Hz, shortening at both higher and lower frequencies, giving rise to a bell-shaped frequency-APD relationship. In muscles treated with daily Ž . doses of amiodarone 50 or 100 mgrkg , APD was prolonged over the entire range of frequencies from 0.1 to 3.0 Hz. Percentage prolongation of APD at each frequency was more or less similar, and the bell-shaped relationship w x observed in control muscles was well preserved 73 . APD prolongation in ventricular myocytes from rabbits treated with chronic amiodarone was also frequency-independent w x within a range of 0.1-3. In Langendorff-perfused rabbit hearts, we investigated the chronic effects of amiodarone on ventricular repolarization in comparison with the acute effects of 3 Class III Ž . w x antiarrhythmic drugs sotalol, E-4031 and MS-551 59 . Forty to 50 electrograms were recorded through modified bipolar electrodes from the anterior to the lateral epicardial Ž . surface of the ventricles under His-bundle pacing 1.0 Hz . In control hearts, epicardial activation proceeded from the apex to the base. The interval from the initial sharp negative deflection of the QRS complex to the apex of the Ž . T-wave Q-aT in the electrograms, which reflects APD at the recording site, was longest at the apex and shortest at the base. Therefore, repolarization proceeded from the base to the apex. In hearts treated with oral amiodarone Ž . 100 mgrkg, 4 weeks , Q-aT was uniformly prolonged by 14-16% throughout the mapped area, whereas the activation sequence was unaffected, and a normal Q-aT gradient was well preserved from the apex to the base. The spatial inhomogeneity of ventricular repolarization was not enhanced by drug treatment. In contrast, acute application of Ž . Ž . Ž . sotalol 30 mM , E-4031 0.1 mM , or MS-551 1 mM caused much greater Q-aT prolongation at the apex than at the base, resulting in a marked enhancement of the spatial w x inhomogeneity of ventricular repolarization 59 . The reduction in ionic current density following chronic treatment with amiodarone might be due to a modulation w x of gene expression of ion channels. Kamiya et al. 64 investigated the expression of Shaker-related potassium channel genes in rats in order to obtain insight on this point. Male Wistar rats aged 6 weeks were treated for 4 weeks with oral amiodarone at a daily dose of 100 mgrkg. The rats were then sacrificed to obtain blood samples and the ventricles. Total RNA was extracted by the standard AGPC method, and Kv1.5 mRNA levels were measured by Northern blot analysis using densitometry of the autoradiogram. The mRNA for Kv1.5 was detected as a single Ž . Ž . band 3.4 kb in both the control n s 7 and amiodarone-Ž . treated groups n s 7 . The amount of Kv1.5 mRNA in the amiodarone-treated rats was significantly less than the Ž . control by 41% on average , suggesting that gene expression of the Kv1.5 channel in the ventricle is modulated Ž . down-regulated by long-term treatment with amiodarone. A down-regulation of the transcriptional activity of the Kv1.5 gene in rat atrial and ventricular muscles following amiodarone treatment was also reported by Peele et al. in w x an abstract 123 .
Ionic currents
Recent molecular biological studies have shown that more than several distinct voltage-gated potassium channel w x genes are expressed in rat cardiac tissues 13,132 . They Ž . include 4 Shaker-related Kv subfamily genes: Kv1.1, Kv1.2, Kv1.4 and Kv1.5. The structural and functional relations of these channels cloned to the native potassium channels remain unclear. Such channel gene products can Ž . form heteromeric potassium channels hetero-tetramers that exhibit current kinetics and pharmacologic properties Ž distinct from the original homomeric channels homo-tetra-. mers . Association of accessory b-subunits with the poreforming a-subunits may also influence the channel properties, leading to a large diversity of the native voltage-gated w x potassium channels 13,33 . From the results presented by w x w x Kamiya et al. 64 and by Peele et al. 123 , it seems intriguing to speculate that chronic amiodarone administration can modulate the gene expression level for potassium channels. Nevertheless, other genes corresponding to a variety of key currents, such as HERG, minK, KvLQT1 or
Desethylamiodarone
It has been shown in pharmacokinetic studies that the Ž . amount of desethylamiodarone DEA accumulated in the myocardium after several weeks of amiodarone treatment is comparable to, or greater than, that of the parent drug w x 12,108,172 . There is a species difference in the extent of w x myocardial accumulation of DEA 145,146 . In isolated cardiac tissues, DEA was shown to have acute effects on action potential configuration qualitatively and quantitaw x tively similar to those of amiodarone 107,120,183 . In ventricular muscles and Purkinje fibers from dogs or guinea Ž . pigs, DEA 1-57 mM , like amiodarone, caused a marked use-dependent V inhibition with similar onset and offset max kinetics. Acute in vitro application of DEA resulted in little or no prolongation of APD in ventricular muscle, and w x a shortening of APD in Purkinje fibers 120,130,183 . An appreciable decrease in spontaneous rate of rabbit SA node w x tissues was also reported 183 . In vivo animal experiments, however, have shown some differences between the two compounds. A single intravenous dose of DEA was 2.6 times as potent as amiodarone in increasing the QRS w x duration in rats 106 , and was also more potent than the parent compound in producing rate-dependent QRS prow x longation in dogs 158 . In contrast, DEA applied intravenously was less potent than amiodarone in frequency-dew x pendent inhibition of AV nodal conduction 107,158 . In radioligand binding studies, both amiodarone and DEA w 3 x were shown to inhibit H BTXB binding to sodium chanw x nels in ventricular myocytes with a similar potency 140 , but the inhibitory action of DEA against binding of w 3 x Ž .w 3 x H nitrendipine or y H desmethoxyverapamil to membranes of heart was less than one-tenth as potent as 
Amiodarone and thyroid hormones

Hypothyroid-like actions of amiodarone
One molecule of amiodarone contains two iodine atoms comprising 37% of its total molecular weight, and it shares w x some structural similarities with thyroid hormones 71,144 . The major electrophysiologic changes of the heart induced Ž by chronic treatment with amiodarone a prolongation of the action potential duration and the refractory period of . all cardiac tissues resemble those induced by hypothyroid- 
Modulation of thyroid hormone action
Three mechanisms have been proposed to explain the Ž . hypothyroid-like effects of chronic amiodarone Fig. 3 . The first is an inhibition of the peripheral conversion from T to T . This was suggested from an observation that 4 3 long-term administration of amiodarone causes a modest Ž decrease in plasma levels of T an active metabolite of 3 . T accompanied by a significant increase in serum T and, 4 4 Ž . in particular, reverse T rT , an inactive metabolite of T by outer-ring deiodination. This process takes place mainly in the liver and kidney, and is predominantly responsible for the production of active thyroid hormone in the blood. Inhibition of this enzyme by amiodarone has been demonstrated in liver and myocardial tissue homogenates from w x rats treated in vivo 10,26,43,124,125,152 and in isolated w x rat hepatocytes 1 . DEA, like amiodarone, was also shown Ž . Ž . tion by Type III 5-deiodinase is unaffected by amiow x darone 66 . Iopanoic acid, a potent inhibitor of the intracellular conversion of T to T , causes similar changes in 4 3 serum thyroid hormones as observed during long-term amiodarone administration, but it has failed to duplicate w x sinus bradycardia 82,152 , reduction of cardiac b-adrenw x ergic receptor density 125 , changes in electrocardiograms w x w x 155 , and antiarrhythmic activity 95 . Therefore, the inhibition of peripheral conversion of T to T by amiodarone 4 3 or DEA cannot account for the major electrophysiological Ž . to reverse T rT . AM andror DEA may also inhibit cellular uptake of 3 3 Ž . T and T as well as T binding to the nuclear receptors TR . 4 3 3
profile of chronic amiodarone, although it may influence the thyroid hormone-dependent metabolism of the heart. The second possible mechanism responsible for the hypothyroid-like effects of chronic amiodarone is an inhibition of transport of iodothyronines through the cell memw x w x brane 67,71,77 . Schroder-van der Elst et al. 138 showed in experiments using rats that entrance of plasma-derived T is compromised in the heart after 3 weeks of oral In experiments using nuclear preparations from myocardial tissue extracts of pig and rat hearts, Gøtzsche and Ørskov w x 44,45 also observed that DEA had a much higher potency than amiodarone in displacing T from its receptor. These 3 discrepancies among investigators could be attributed in part to the different tissues investigated, and in part to the different methods employed. Low solubility of amiodarone in the nuclear preparation under assay conditions, and Ž . intrinsic effects of a vehicle Tween 80 on T binding to 3 TR have been considered to make data interpretation more w x difficult 9,118,179 .
Since the cloning of genes encoding TR, at least 4 TR isoforms have been identified: TR-a1, TR-b1, TR-b2 and w x TRa-2 54,80,156 . Recent studies have suggested that the T binding inhibitory effects of amiodarone or DEA for 3 each TR isoform may be different in potency and mode of w x antagonism 9,34,167 . Such TR isoform-dependent effects might account for the tissue selectivity of the drug action, although the issue remains to be investigated.
T antagonism 3
Chronic effects of amiodarone could be mediated by T 3 w x antagonism at a cellular or subcellular level 118,121 . Guo 
Summary and conclusions
The complex profile of amiodarone actions on the electrophysiological properties of cardiac cells reviewed in this article may be summarized as follows. As acute effects, amiodarone inhibits both inward and outward currents. The inhibition of inward Na q and Ca 2q currents is enhanced in a use-and voltage-dependent manner, resulting in suppression of excitability and conductivity in both i -and i -dependent cardiac tissues. The inhibition is Na Ca greater in the tissues stimulated at higher frequencies, and Ž . in those with less negative resting or diastolic membrane Ž . potentials. As outward currents, i i and i , i be inhibited at high concentrations of amiodarone. Acute effects of amiodarone on i remain unclear. Previous to reports on the acute effects of amiodarone on APD are conflicting, presumably because different ionic currents are responsible for the repolarization of action potential in different animal species, cardiac tissues and experimental conditions. APD would be shortened if the inhibitory action of amiodarone on the inward current is greater than on the outward current, and vice versa in the opposite case. The major and consistent chronic effect of amiodarone is a moderate APD prolongation with minimal frequencydependence. This prolongation is most likely due to a decrease in the current density of i and i . Chronic K t o effects of amiodarone are modulated by tissue accumulation of amiodarone and DEA. Variable suppression of excitability and conductivity of the heart by chronic amiodarone might reflect direct acute effects of the parent drug Ž . andror its active metabolite DEA retained at the sites of action. Chronic amiodarone was shown to cause a downregulation of Kv1.5 mRNA in rat hearts, suggesting a drug-induced modulation of potassium channel gene expression.
Electrophysiological changes in the heart induced by chronic amiodarone resemble those induced by hypothyroidism. Three mechanisms have been proposed to explain this hypothyroid-like action of amiodarone. Amiodarone andror DEA may inhibit peripheral conversion from T to T , cellular uptake of T and T , and T binding Ž . to nuclear receptors TR . The second and third mechanisms are considered to be more important than the first. Amiodarone or DEA could antagonize T action on the 3 heart at a cellular or subcellular level.
Two distinct characteristics in the cellular electropharmacology of amiodarone are different from those of other antiarrhythmic drugs. First, it acts on many different types of molecular targets including Na q , Ca 2q , and K q channels as well as adrenoceptors. Second, it may cause antiar-( )rhythmic remodeling of cardiac cells, probably through a modulation of gene expression of ion channels and other functional proteins. We hypothesize that this remodeling is mediated most likely by cellular or subcellular T antago-3 nism. Nevertheless, much remains to be studied as to the acute and especially chronic effects of amiodarone on ionic currents, transporters, receptors and other molecules in cardiac cells. The role of the cardiac hypothyroid state in the genesis of antiarrhythmic activity is still a matter of considerable controversy among investigators. Recently, Ž . two amiodarone analogues SR 33589 and ATI-2001 showing a potent acute antiarrhythmic activity in animal w x models, have been developed 37,87,88,131 . These new compounds are not known to exhibit chronic antiarrhythmic potential or cardiac hypothyroidism activity. Unravelling these issues will be required to understand the exact molecular and cellular mode of action of amiodarone and to find a new direction for the development of the ideal antiarrhythmic drugs of the future. 
